OncoMatch/Clinical Trials/NCT05578326
Study of Trilaciclib and Lurbinectidin
Is NCT05578326 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Trilaciclib and Lurbinectedin for lung cancer.
Treatment: Trilaciclib · Lurbinectedin — Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response is short, typically 4 months. Following progression after the 1st line treatment of SCLC, there is no consensus regarding subsequent therapy. Lurbinectedin is FDA approved and is increasingly preferred in clinical practice. Toxicity was significant, but appeared favorable compared to historic results with topotecan, leading to the adoption of this therapy for second-line SCLC. The toxicity profile was dominated by myelosuppression. This study investigates the effect of Trilaciclib on myelosuppression rate in subjects with platinum refractory extensive stage (ES)- SCLC receiving Lurbinectedin as well as the clinical synergy of Trilaciclib and Lurbinectedin combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Previous treatment with a platinum agent
Must have received: anti-PD-1 therapy
Previous treatment with a PD1 agent
Must have received: anti-PD-L1 therapy
Previous treatment with a PDL1 agent
Cannot have received: investigational drug
Treatment with any investigational drug within 4 weeks prior to start of treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Hitchcock Medical Center · Lebanon, New Hampshire
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify